Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients Meeting Abstract
| Authors: | Segal, N. H.; Kemeny, N. E.; Cercek, A.; Reidy, D. L.; Raasch, P. J.; Warren, P.; Hrabovsky, A. E.; Campbell, N.; Shia, J.; Goodman, K. A.; Erinjeri, J. P.; Solomon, S. B.; Yamada, Y.; Saltz, L. |
| Abstract Title: | Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 180s |
| Language: | English |
| ACCESSION: | WOS:000404665404256 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.3539 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3539 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
